Introduction
Human coagulation factor VIIa is approved to treat bleeding in hemophilia patients with inhibitors. Two theories attempt to explain why high doses of FVIIa are required for hemostasis. The tissue factor (TF)-dependent mechanism suggests that FVIIa's hemostatic effect requires its binding to TF, which is expressed on cell surfaces at the site of injury. 1, 2 In this scenario, the high concentration of FVIIa must compete with endogenous FVII for TF. The alternative phospholipiddependent mechanism postulates that FVIIa binds phospholipids on the platelet surface and activates factor X. Because FVIIa has low affinity for phospholipid, a high concentration of FVIIa is required to achieve hemostasis. 3, 4 Related to the platelet-binding mechanism, the possibility that platelet GP1ba binds FVIIa and contributes to its TF-independent activity has also been proposed. 5 Recently, Shibeko et al 6 used in vitro data and mathematical modeling and concluded that both mechanisms contribute to enhanced thrombin generation but that the TF-dependent mechanism dominates.
To test whether the TF pathway is dominant, we used a chimeric FVIIa molecule, mFIX gla-egf1 FVIIa, with minimal affinity for TF. FVIIa is a multidomain enzyme containing an amino-terminal g-carboxyglutamic acid-rich (Gla) domain, 2 epidermal growth factor (EGF)-like domains, and a trypsin-like serine protease domain. Previous studies indicate that the Gla domain, the first EGF domain (EGF1), and the protease domain all contribute to TF binding. 7, 8 Furthermore, our unpublished observations indicate that the affinity of human FIXgla-egf1FVIIa for TF is reduced about 600 000-fold compared with wtFVIIa. Our chimeric mFVIIa molecule, mFIX gla-egf1 FVIIa, has had its Gla and EGF1 domains replaced by those of mouse FIX (which has a similar domain structure); its functional affinity for TF is reduced to unmeasurable levels, yet its ability to catalyze the conversion of FX to FXa in the presence of 
Study design
Mouse complementary DNAs were cloned and proteins purified as previously described. [8] [9] [10] Insertion of the short amino acid sequence RKRRKR between R193 and I194 was performed as described previously so that secreted FVIIa is activated when secreted.
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TF-dependent FX activation used human TF (Innovin; DADE/ Behring, Deerfield, IL) or mouse TF-containing microparticles. 12 Binding was inferred by the ability of the complex to convert FX to FXa, as measured by its ability to cleave Spectrozyme FXa (American Diagnostica). 8 Clotting activity used a standard curve with NovoSeven (Novo Nordisk, Bagsvaerd, Denmark). Prothrombin time (PT) assays used human FVIIdeficient plasma; activated partial thromboplastin time (APTT) assays used human FIX-deficient plasma (both from George King Bio-Medical, Overland Park, KS) using a START 4 Coagulation Analyzer (Diagnostica Stago, Asnieres, France). There is an Inside Blood commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. For personal use only. on April 14, 2017. by guest www.bloodjournal.org From Animal experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of North Carolina. All experiments used 6-to 10-week-old hemophilia B mice on a C57BL/6 background. Saphenous vein bleeding was performed as described elsewhere. 13 The saphenous vein model is sensitive to TF. The average time to hemostasis (ATTH) in homozygous mice with low TF (Parry et al) 14 was doubled, relative to either wild-type (WT) mice or heterozygous littermates (data not shown). This result is consistent with tail-bleeding studies in low-TF mice. 15 
Results and discussion
We did 2 tests to ensure that FIX gla-egf1 FVIIa is not TF dependent. First, we examined the intrinsic and extrinsic coagulation activity of mFVIIa and mFIX gla-egf1 FVIIa in TF-independent APTT assays ( Figure 1A ) and TF-dependent PT assays ( Figure 1B) . Mouse FIX gla-egf1 FVIIa has the same APTT activity as does mFVIIa (P 5 .63) ( Figure 1A) ; however, mFIX gla-egf1 FVIIa has no PT activity when compared with mFVIIa ( Figure 1B) , which indicates that mFIX gla-egf1 FVIIa does not bind to TF.
Second, we measured whether mFIX gla-egf1 FVIIa catalyzes the conversion of FX to FXa. Mouse FVIIa binds to human TF in a concentration-dependent manner to catalyze the conversion of FX to FXa. However, mFIX gla-egf1 FVIIa exhibits no measurable TF-dependent FXa generation ( Figure 1C) . Similarly, mFVIIa is functional with mouse TF-bearing microparticles, but mFIX gla-egf1 FVIIa is not ( Figure 1D ).
The effect of mFVIIa on hemostasis in the hemophilia B mouse was examined by the saphenous vein bleeding model ( Figure 2B ). 13 Three different concentrations of mFVIIa or mFIX gla-egf1 FVIIa were infused into hemophilia B mice 10 minutes before saphenous vein incision; the time to hemostasis for each bleeding event was recorded over a 30-minute time period and the ATTH for each mouse was calculated. Control WT C57BL/6 mice (n 5 4) had a median ATTH of 44 seconds; hemophilia B mice (n 5 3) failed to achieve hemostasis within the 30-minute experimental time frame. The median ATTH remained similar for mFVIIa-and mFIX gla-egf1 FVIIatreated hemophilia B mice at the 3 tested doses.
Clearly, FIX gla-egf1 FVIIa does not productively bind TF; however, there are other differences in these molecules that may affect their function. For example, FIX's Gla domain alone is sufficient for binding to collagen IV in the subendothelium. 16, 17 Thus, it is possible that Figure 1 . Characterization of mFIX gla-egf1 FVIIa and hFIX gla-egf1 FVIIa. (A) Relative coagulant activity of mFIXgla-egf1FVIIa compared with recombinant mFVIIa in an APTT assay; 25 mL of mFVIIa or mFIXglaegf1FVIIa (5 mg/mL) was added to 25 mL FIX -deficient human plasma and 25 mL APTT reagent, and the assay initiated with 25 mL CaCl. (B) Relative activity of mFIXgla-egf1FVIIa compared with recombinant mFVIIa in a PT assay; 25 mL of either mFVIIa or mFIXglaegf1FVIIa (0.5 mg/mL) was added to 25 mL FVII-deficient plasma, and 100 mL Innovin was added to initiate the reaction. The Innovin concentration was determined by titration with human FVIIa. Data were derived from at least 3 experimental points. Data are shown as average 6 1 standard deviation (SD). (C) Functional binding of 5000 ng/mL mFVIIa and mFIXgla-egf1FVIIa to Innovin (human TF), measured by FXa generation and detected with an FXa chromogenic substrate. Absorbance was measured after 15 minutes. Backgrounds were subtracted. (D) Relative functional binding of 5000 ng/mL mFIXgla-egf1FVIIa compared with mFVIIa to mouse TF-positive microparticles. Substrate (S-2288, 2 mM final concentration) was added to the reaction and the absorbance at 405 nm was determined after 15 minutes. Backgrounds were subtracted. The Mann-Whitney U test was used for all statistical analysis. ND, not detectable; OD, optical density. Figure 2 . Effect of FIX gla-egf1 FVIIa chimera on saphenous vein bleeding in the hemophilia B mouse. Wild-type (control group) or hemophilia B (experimental group) mice were subjected to saphenous vein incision. After initial clot formation, the clot was disrupted repeatedly for 30 minutes and the time for each clot to form was measured; the average time to clot formation was calculated for each mouse. Ten minutes before incision, mFVIIa or mFIXgla-egf1FVIIa was injected into Hemophilia B mice. The hemophilic mice bled continuously during the entire 1800-second duration of the experiment; WT mice have an ATTH of 44 seconds. Each point represents the average of multiple bleeding times in each mouse during the 30-minute observation time. For 2 mg/kg, median ATTH was 37 seconds (n 5 4) for mFVIIa-treated hemophilia B mice and 47 seconds for mFIXgla-egf1FVIIa-treated mice (n 5 6). The difference in ATTH was not statistically significant (P 5 .24); both are significantly shorter than untreated hemophilia B mice (P , .05). For 1 mg/kg, mFVIIa-treated hemophilia B mice (n 5 5) clotted in an average of 108 seconds; the ATTH was 97 seconds for mFIXgla-egf1FVIIa-treated hemophilia B mice (n 5 6) (P 5 .75). At a dose of 0.25 mg/kg, the median ATTH for mFVIIa-treated mice (n 5 5) was 86 seconds, whereas for mFIXgla-egf1FVIIa-treated mice (n 5 5) it was 111 seconds (P 5 .83). All P values were calculated using the nonparametric MannWhitney U test. HB, hemophilia B. For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From modified pharmacokinetics of FVIIa compared with FIXgla-egf1FVIIa due to additional interactions within the mouse circulation may explain some of our data.
Hemophilia B mice require much higher doses of FVIIa than do humans to correct bleeding. Our 2-mg/kg dose is higher than the 90-to 270-mg/kg dose currently recommended for human use; however, it is consistent with others' observations. 18 For example, Ivanciu et al report that 5 mg/kg of mouse or human FVIIa prevents bleeding equally well in a hemophilia B mouse. 18 Because the affinity of human FVIIa for mouse TF is 1000-fold less than that of mFVIIa for mouse TF, this is further evidence that pharmacologic use of FVIIa does not require TF for hemostasis. 19 In summary, FIXgla-egf1 does not productively bind TF but is as effective as mFVIIa in promoting hemostasis in a hemophilia B mouse. Blood-cell-derived TF is the decisive trigger for the massive fibrin deposition of deep vein thrombosis. 20 Moreover, long-term high levels of FVIIa expression in mice cause premature death related to thrombosis in the lung and heart, both tissues rich in TF. 11 Thus, because FIX gla-egf1 FVIIa does not bind TF, it is likely a safer and more effective molecule than FVIIa, especially for those cases where FVIIa is used off-label for uncontrolled bleeding.
